HC Wainwright Has Negative Estimate for MCRB FY2026 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Equities researchers at HC Wainwright reduced their FY2026 earnings estimates for shares of Seres Therapeutics in a research report issued on Wednesday, November 4th. HC Wainwright analyst M. Keller now forecasts that the biotechnology company will post earnings of ($6.78) per share for the year, down from their previous estimate of ($6.33). The consensus estimate for Seres Therapeutics’ current full-year earnings is ($6.33) per share. HC Wainwright also issued estimates for Seres Therapeutics’ Q4 2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.77) EPS and FY2028 earnings at ($1.87) EPS.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.63). Seres Therapeutics had a negative return on equity of 175.40% and a negative net margin of 2,209.55%. The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $6.35 million.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Stock Performance

MCRB opened at $2.09 on Friday. The stock has a 50-day moving average of $3.40 and a 200-day moving average of $6.91. Seres Therapeutics has a 52-week low of $1.67 and a 52-week high of $29.98.

Institutional Investors Weigh In On Seres Therapeutics

A hedge fund recently bought a new position in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new position in Seres Therapeutics, Inc. (NASDAQ:MCRB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.